Trial
NCT00982657
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Pfizer
Collaborators
—
Condition
Solid Tumor
Intervention
CVX-060 + sunitinib
Why stopped
Refer to statement in Summary Section/Detailed Description
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-11-20